U.S. Patents Awarded to Inventors in Massachusetts (Jan. 18)

(Targeted News Service Via Acquire Media NewsEdge) Targeted News Service Targeted News Service ALEXANDRIA, Va., Jan. 18 -- The following federal patents were awarded to inventors in Massachusetts.

*** Cisco Technology Assigned Patent for Failure Protection for P2MP Tunnel Tail-end Node ALEXANDRIA, Va., Jan. 18 -- Cisco Technology, San Jose, Calif., has been assigned a patent (8,355,315) developed by Jean-Phillippe Vasseur, Dunstable, Mass., Alton Lo, Fremont, Calif., and Mohammed Azhar Sayeed, Shrewsbury, Mass., for a "failure protection for P2MP tunnel tail-end node." The abstract of the patent published by the U.S. Patent and Trademark Office states: "In one embodiment, a primary tail-end node (PTE) of a point-to-multipoint (P2MP) tunnel selects a backup tail-end node (BTE) from one or more BTEs that are configured to forward traffic to a same multicast network as the PTE. The PTE then determines a branching node of the P2MP tunnel to reach the PTE and the selected BTE, and notifies the branching node of the selected BTE. In response, the branching node establishes a backup tunnel to the selected BTE, and redirects P2MP traffic onto the backup tunnel to the selected BTE in response to a detected failure of the PTE." The patent application was filed on Nov. 27, 2006 (11/604,622). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,355,315&OS=8,355,315&RS=8,355,315 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** General Hospital Assigned Patent for Method and Apparatus for Performing Optical Imaging Using Frequency-domain Interferometry ALEXANDRIA, Va., Jan. 18 -- General Hospital, Boston, has been assigned a patent (8,355,138) developed by four co-inventors for a "method and apparatus for performing optical imaging using frequency-domain interferometry." The co-inventors are Seok-Hyun Yun, Cambridge, Mass., Brett Eugene Bouma, Quincy, Mass., Guillermo J. Tearney, Cambridge, Mass., and Johannes Fitzgerald De Boer, Amstelveen, The Netherlands.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "An apparatus and method are provided. In particular, at least one first electro-magnetic radiation may be provided to a sample and at least one second electro-magnetic radiation can be provided to a non-reflective reference. A frequency of the first and/or second radiations varies over time. An interference is detected between at least one third radiation associated with the first radiation and at least one fourth radiation associated with the second radiation. Alternatively, the first electro-magnetic radiation and/or second electro-magnetic radiation have a spectrum which changes over time. The spectrum may contain multiple frequencies at a particular time. In addition, it is possible to detect the interference signal between the third radiation and the fourth radiation in a first polarization state. Further, it may be preferable to detect a further interference signal between the third and fourth radiations in a second polarization state which is different from the first polarization state. The first and/or second electro-magnetic radiations may have a spectrum whose mean frequency changes substantially continuously over time at a tuning speed that is greater than 100 Tera Hertz per millisecond." The patent application was filed on July 27, 2011 (13/191,885). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,355,138&OS=8,355,138&RS=8,355,138 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Raytheon Assigned Patent ALEXANDRIA, Va., Jan. 18 -- Raytheon, Waltham, Mass., has been assigned a patent (8,355,255) developed by Scott R. Cheyne, Brookline, N.H., Jeffrey Paquette, Wakefield, Mass., and Mark Ackerman, Sudbury, Mass., for "cooling of coplanar active circuits." The abstract of the patent published by the U.S. Patent and Trademark Office states: "In one aspect, a system includes a first circuit board that includes integrated circuits, a first thermal spreader coupled to the integrated circuits of the first circuit board, a first compliant board coupled to the first circuit board, a second circuit board that includes integrated circuits and a second thermal spreader coupled to the integrated circuits of the second circuit board. The first circuit board and the first thermal spreader have a first thickness. The second daughter board and the second thermal spreader have a second thickness. The system further includes a second compliant board coupled to the second circuit board, a board assembly coupled to first and second compliant boards and a cold-plate assembly in contact with the first and second thermal spreaders. Either of the first or the second compliant boards is configured to expand or contract to account for the differences between the first and second thicknesses." The patent application was filed on Dec. 22, 2010 (12/975,731). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,355,255&OS=8,355,255&RS=8,355,255 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Thermo Scientific Portable Analytical Instruments Assigned Patent ALEXANDRIA, Va., Jan. 18 -- Thermo Scientific Portable Analytical Instruments, Tewksbury, Mass., has been assigned a patent (8,355,126) developed by John E. Goulter, Northridge, Calif., Mark Hamilton, Upton, Mass., and Pratheev Sreetharan, Medford, Mass., for a "hand-held, self-contained optical emission spectroscopy (OES) analyzer." The abstract of the patent published by the U.S. Patent and Trademark Office states: "A hand-held, self-contained, battery-powered test instrument for analyzing composition of a sample includes an exciter for exciting at least a portion of the sample, a compact cross-dispersed spectrometer for receiving an optical signal from the excited portion of the sample and a processor for processing spectral data about the optical signal from the spectrometer. The exciter may include a spark generator and a counter electrode, a laser or other device for generating the optical signal from the sample portion. The spectrometer has a wavelength range broad enough to enable the test instrument to detect and determine relative quantities of carbon, phosphorous, sulfur, manganese, silicon, iron and other elements necessary to identify common alloys. The spectrometer includes a structural member made of a light-weight material having a small coefficient of thermal expansion (CTE). The spectrometer is dimensionally stable over a range of expected ambient temperatures, without controlling the temperature of the spectrometer." The patent application was filed on Feb. 22, 2008 (12/036,039). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,355,126&OS=8,355,126&RS=8,355,126 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Qualcomm Assigned Patent for MIMO System with Multiple Spatial Multiplexing Modes ALEXANDRIA, Va., Jan. 18 -- Qualcomm, San Diego, has been assigned a patent (8,355,313) developed by four co-inventors for a "MIMO system with multiple spatial multiplexing modes." The co-inventors are J. Rodney Walton, Carlisle, Mass., John W. Ketchum, Harvard, Mass., Mark S. Wallace, Bedford, Mass., and Steven J. Howard, Ashland, Mass.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "A MIMO system supports multiple spatial multiplexing modes for improved performance and greater flexibility. These modes may include (1) a single-user steered mode that transmits multiple data streams on orthogonal spatial channels to a single receiver, (2) a single-user non-steered mode that transmits multiple data streams from multiple antennas to a single receiver without spatial processing at a transmitter, (3) a multi-user steered mode that transmits multiple data streams simultaneously to multiple receivers with spatial processing at a transmitter, and (4) a multi-user non-steered mode that transmits multiple data streams from multiple antennas (co-located or non co-located) without spatial processing at the transmitter(s) to receiver(s) having multiple antennas. For each set of user terminal(s) selected for data transmission on the downlink and/or uplink, a spatial multiplexing mode is selected for the user terminal set from among the multiple spatial multiplexing modes supported by the system." The patent application was filed on May 5, 2008 (12/115,522). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,355,313&OS=8,355,313&RS=8,355,313 Written by Satyaban Rath; edited by Hemanta Panigrahi.

*** Merck, Sharp & Dohme Assigned Patent ALEXANDRIA, Va., Jan. 18 -- Merck, Sharp & Dohme, Rahway, N.J., and Istituto di Ricerche di Biologia Molecolare P Angeletti, Rome, have been assigned a patent (8,354,545) developed by Shawn J. Stachel, Perkasie, Pa., Thomas Steele, Schwenksville, Pa., and Alessia Petrocchi, Boston, for "3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease." The abstract of the patent published by the U.S. Patent and Trademark Office states: "The present invention is directed to 3,4-substituted pyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved. ##STR00001##." The patent application was filed on Dec. 10, 2008 (12/747,605). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=83,54,545.PN.&OS=PN/83,54,545&RS=PN/83,54,545 Written by Amal Ahmed; edited by Jaya Anand.

*** Massachusetts Institute of Technology Assigned Patent ALEXANDRIA, Va., Jan. 18 -- Massachusetts Institute of Technology, Cambridge, Mass., has been assigned a patent (8,354,555) developed by Francesco Stellacci, Somerville, Mass., and Benjamin Wunsch, Cambridge, Mass., for "monolayer-coated surfaces as catalytic platforms for organic reactions." The abstract of the patent published by the U.S. Patent and Trademark Office states: "This invention provides a method for increasing the activity of catalysts. The method requires the introduction of the catalyst into nano-structured surfaces. The catalysts are introduced as functional groups in molecules forming a monolayer on a surface. A mixed monolayer of catalyst and inert molecules generates ordered domains of molecules on the surface. The catalyst is confined in regions of 0.5 nm to 3 nm in size and is surrounded by an inert material. The presence of such ordered domains that commensurate in size with the reactants, enhance the performance of the catalyst and increase the rate of the reaction." The patent application was filed on May 22, 2009 (12/470,586). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=83,54,555.PN.&OS=PN/83,54,555&RS=PN/83,54,555 Written by Amal Ahmed; edited by Jaya Anand.

*** Concert Pharmaceuticals Assigned Patent ALEXANDRIA, Va., Jan. 18 -- Concert Pharmaceuticals, Lexington, Mass., has been assigned a patent (8,354,557) developed by four co-inventors for a "synthesis of deuterated morpholine derivatives." The co-inventors are Julie F. Liu, Lexington, Mass., Xuejun Tang, Ellicott City, Md., Scott L. Harbeson, Cambridge, Mass., and Craig E. Masse, Cambridge, Mass.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "The present invention is directed to a process for preparing a 2,26,6-d.sub.4-morpholine derivative represented by Structural Formula (I): ##STR00001## or a salt thereof." The patent application was filed on June 17, 2009 (12/456,507). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=83,54,557.PN.&OS=PN/83,54,557&RS=PN/83,54,557 Written by Amal Ahmed; edited by Jaya Anand.

*** Alkermes Assigned Patent ALEXANDRIA, Va., Jan. 18 -- Alkermes, Waltham, Mass., has been assigned a patent (8,354,534) developed by four co-inventors for selective opioid compounds. The co-inventors are Derrick Arnelle, Arlington, Mass., Daniel Deaver, Franklin, Mass., Reginald L. Dean III, Boxborough, Mass., and Mark Todtenkopf, Franklin, Mass.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which relates to morphinan compounds useful as .mu., .delta., and/or .kappa. receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents." The patent application was filed on Feb. 13, 2009 (12/371,334). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=83,54,534.PN.&OS=PN/83,54,534&RS=PN/83,54,534 Written by Amal Ahmed; edited by Jaya Anand.

*** Coley Pharmaceutical, Coley Pharmaceutical Group Assigned Patent ALEXANDRIA, Va., Jan. 18 -- Coley Pharmaceutical, Langenfeld, Germany, and Coley Pharmaceutical Group, Wellesley, Mass., have been assigned a patent (8,354,522) developed by Alexandra Forsbach, Ratingen, Germany, Jorg Vollmer, Dusseldorf, Germany, and Grayson B. Lipford, Watertown, Mass., for immunostimulatory oligoribonucleotides.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs, adducts, and combinations thereof are provided. Compositions of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency. Immunostimulatory oligoribonucleotides of the invention are believed to stimulate Toll-like receptor 8 (TLR8)." The patent application was filed on March 14, 2011 (13/046,871). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=83,54,522.PN.&OS=PN/83,54,522&RS=PN/83,54,522 Written by Amal Ahmed; edited by Jaya Anand.

*** General Hospital Assigned Patent ALEXANDRIA, Va., Jan. 18 -- General Hospital, Boston, has been assigned a patent (8,355,772) developed by Van J. Wedeen, Sommerville, Mass., for a cross-fiber diffusion MRI.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "A method for processing MRI data in which a reference direction and a first voxel are selected. A first transverse orientation vector associated with the first voxel is determined. This first transverse orientation vector is normal to the reference direction. On the basis of the first transverse orientation vector, a second voxel is selected. A second transverse orientation vector associated with the second voxel is also selected. This second transverse orientation vector is likewise normal to the reference direction. The method also includes determining whether a relationship between the first and second transverse orientation vectors is consistent with a track normal to the reference direction and extending between the first and second voxels." The patent application was filed on March 10, 2006 (11/817,613). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,355,772.PN.&OS=PN/8,355,772&RS=PN/8,355,772 Written by Kusum Sangma; edited by Anand Kumar.

*** Massachusetts Institute of Technology Assigned Patent ALEXANDRIA, Va., Jan. 18 -- Massachusetts Institute of Technology, Cambridge, Mass., has been assigned a patent (8,355,767) developed by five co-inventors for a "Raman spectroscopy for non-invasive glucose measurements." The co-inventors are Martin Hunter, Bradford, Mass., Annika Enejder, Goteborg, Sweden, Thomas Scecina, Medfield, Mass., Michael Feld, Jamaica Plain, Mass., and Wei-Chuan Shih, Cambridge, Mass.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "The present invention relates to the use of Raman spectroscopy for quantitative, non-invasive transcutaneous measurement of blood analytes, such as glucose. Raman spectroscopy is used to measure glucose transcutaneously, in patients whose blood glucose levels were monitored. Raman spectra were collected transcutaneously along with glucose reference values provided by standard capillary blood analysis. A partial least squares calibration was created from the data from each subject and validated using leave-one-out cross validation." The patent application was filed on April 27, 2006 (11/412,418). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,355,767.PN.&OS=PN/8,355,767&RS=PN/8,355,767 Written by Kusum Sangma; edited by Anand Kumar.

*** Airvana Assigned Patent ALEXANDRIA, Va., Jan. 18 -- Airvana, Chelmsford, Mass., has been assigned a patent (8,355,727) developed by Minh Hoang, Acton, Mass., and Kenneth Jones, Atkinson, N.H., for a "proximity detection in a network." The abstract of the patent published by the U.S. Patent and Trademark Office states: "Techniques for facilitating a hand-in using proximity-detection and dual-pilot operation detect a presence of a client device in proximity to the network-side device; and transmit a first signal over a first communication channel to the client device, the first signal enabling the client device to access information transmitted in a second signal from the network-side device." The patent application was filed on Dec. 19, 2007 (11/960,026). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,355,727.PN.&OS=PN/8,355,727&RS=PN/8,355,727 Written by Kusum Sangma; edited by Anand Kumar.

*** Massachusetts Institute of Technology Assigned Patent ALEXANDRIA, Va., Jan. 18 -- Massachusetts Institute of Technology, Cambridge, Mass., has been assigned a patent (8,354,960) developed by Steven Ira Krich, Lexington, Mass., Cory J. Prust, Waukesha, Wis., and Ian Weiner, Braintree, Mass., for a "method for low sidelobe operation of a phased array antenna having failed antenna elements." The abstract of the patent published by the U.S. Patent and Trademark Office states: "Described is a method of modifying an antenna pattern for a phased array antenna having at least one failed antenna element. A number of proximate beamformers in a proximate angular region about a beamformer at an angle of interest are determined. Each of the proximate beamformers has a proximate beamformer weight vector. A corrected beamformer weight vector is determined for the angle of interest as a linear combination of the proximate beamformer weight vectors. Each element of the corrected beamformer weight vector that corresponds to one of the failed antenna elements has a value of zero. The method enables computation of low spatial sidelobe antenna patterns without requiring a recalibration of the antenna thereby enabling uninterrupted operation of systems that employ phased array antennas. The method can also be used to control taper loss or sidelobe level for phased array antennas that have no failed antenna elements." The patent application was filed on March 24, 2011 (13/070,688). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,354,960.PN.&OS=PN/8,354,960&RS=PN/8,354,960 Written by Kusum Sangma; edited by Anand Kumar.

*** Varian Semiconductor Equipment Associates Assigned Patent ALEXANDRIA, Va., Jan. 18 -- Varian Semiconductor Equipment Associates, Gloucester, Mass., has been assigned a patent (8,354,655) developed by four co-inventors for a "method and system for controlling critical dimension and roughness in resist features." The co-inventors are Ludovic Godet, Boston, Christopher J. Leavitt, Gloucester, Mass., Joseph C. Olson, Beverly, Mass., and Patrick M. Martin, Ipswich, Mass.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "A method of treating a photoresist relief feature having an initial line roughness and an initial critical dimension. The method may include directing ions toward the photoresist in a first exposure at a first angular range and first dose rate and a that is configured to reduce the initial line roughness to a second line roughness. The method may also include directing ions toward the photoresist relief feature in a second exposure at a second ion dose rate greater than the first dose rate, wherein the second ion dose rate is configured to swell the photoresist relief feature." The patent application was filed on May 3, 2011 (13/099,432). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,354,655&OS=8,354,655&RS=8,354,655 Written by Arpi Sharma; edited by Anand Kumar.

*** QD Vision Assigned Patent ALEXANDRIA, Va., Jan. 18 -- QD Vision, Lexington, Mass., has been assigned a patent (8,354,785) developed by four co-inventors for "nanocrystals including a group IIIA element and a group VA element, method, composition, device and other products." The co-inventors are Christopher R. Clough, East Cambridge, Mass., Craig Breen, Somerville, Mass., Jonathan S. Steckel, Bedford, Mass., and Ebenezer Selwyn Arun Thambaw, Sayoy, Ill.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "A nanocrystal comprising a semiconductor material comprising one or more elements of Group IIIA of the Periodic Table of Elements and one or more elements of Group VA of the Periodic Table of Elements, wherein the nanocrystal is capable of emitting light having a photoluminescence quantum efficiency of at least about 30% upon excitation. Also disclosed is a nanocrystal including a core comprising a first semiconductor material comprising one or more elements of Group IIIA of the Periodic Table of Elements and one or more elements of Group VA of the Periodic Table of Elements, and a shell disposed over at least a portion of the core, the shell comprising a second semiconductor material, wherein the nanocrystal is capable of emitting light having a photoluminescence quantum efficiency of at least about 30% upon excitation. Also disclosed is a nanocrystal comprising a nanocrystal core and a shell comprising a semiconductor material disposed on at least a portion of the nanocrystal core, wherein the semiconductor material comprises at least three chemical elements and is obtainable by a process comprising adding a precursor for at least one of the chemical elements of the semiconductor material from a separate source to a nanocrystal core while simultaneously adding amounts of precursors for the other chemical elements of the semiconductor material. A population of nanocrystals, method for preparing nanocrystals, compositions, and devices including nanocrystals are also disclosed." The patent application was filed on May 21, 2009 (12/454,706). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,354,785&OS=8,354,785&RS=8,354,785 Written by Arpi Sharma; edited by Anand Kumar.

*** Varian Semiconductor Equipment Associates Assigned Patent for Techniques for Manufacturing Solar Cells ALEXANDRIA, Va., Jan. 18 -- Varian Semiconductor Equipment Associates, Gloucester, Mass., has been assigned a patent (8,354,653) developed by Steven M. Anella, West Newbury, Mass., for "techniques for manufacturing solar cells." The abstract of the patent published by the U.S. Patent and Trademark Office states: "Techniques for manufacturing solar cells are disclosed. In one particular exemplary embodiment, the technique may be comprise disposing the solar cell downstream of an ion source; disposing a mask between the ion source and the solar cell, the mask including a front surface, a back surface, and at least one aperture extending in an aperture direction from the front surface to the back surface; and directing ions from the ion source to the solar cell along an ion beam path and through the at least one aperture of the mask, where the ion beam path may be non-parallel relative to the aperture direction." The patent application was filed on Sept. 9, 2009 (12/555,917). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,354,653&OS=8,354,653&RS=8,354,653 Written by Arpi Sharma; edited by Anand Kumar.

*** Lutron Electronics Assigned Patent ALEXANDRIA, Va., Jan. 18 -- Lutron Electronics, Coopersburg, Pa., has been assigned a patent (8,354,803) developed by six co-inventors for a hybrid light source. The co-inventors are Robert C. Newman Jr., Emmaus, Pa., Keith Joseph Corrigan, Allentown, Pa., Aaron Dobbins, Hopedale, Mass., Mehmet Ozbek, Allentown, Pa., Mark Taipale, Harleysville, Pa., and Joel S. Spira, Coopersburg, Pa.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "A hybrid light source comprises a discrete-spectrum lamp (for example, a fluorescent lamp) and a continuous-spectrum lamp (for example, a halogen lamp). A control circuit individually controls the amount of power delivered to the discrete-spectrum lamp and the continuous-spectrum lamp in response to a phase-controlled voltage generated by a connected dimmer switch, such that a total light output of the hybrid light source ranges throughout a dimming range. The continuous-spectrum lamp is driven by a continuous-spectrum lamp drive circuit, which is operable to conduct a charging current of a power supply of the dimmer switch and to provide a path for enough current to flow through the hybrid light source, such that the magnitude of the current exceeds rated latching and holding currents of a thyristor of the dimmer." The patent application was filed on May 21, 2012 (13/476,433). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,354,803&OS=8,354,803&RS=8,354,803 Written by Arpi Sharma; edited by Anand Kumar.

*** KD Secure Assigned Patent ALEXANDRIA, Va., Jan. 18 -- KD Secure, Tallahassee, Fla., has been assigned a patent (8,354,926) developed by John J. Donovan, Hamilton, Mass., and Daniar Hussain, Johnstown, Pa., for "systems and methods for business process monitoring." The abstract of the patent published by the U.S. Patent and Trademark Office states: "The present invention is a method to ensure business processes are followed, comprising the steps of capturing sensory data from one or more sensors; storing the sensory data from the one or more sensors in a data storage device; processing the sensory data from the sensors to detect primitive events in the sensory data using a computer processor; correlating two or more primitive events, weighted by attribute data representing information about the sensors used to sense the primitive events, to determine one or more correlated events using the computer processor; and performing one or more actions to ensure business processes are followed based on the correlation performed in the correlating step." The patent application was filed on March 4, 2012 (13/411,602). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,354,926.PN.&OS=PN/8,354,926&RS=PN/8,354,926 Written by Kusum Sangma; edited by Anand Kumar.

*** UTI, General Hospital Assigned Patent ALEXANDRIA, Va., Jan. 18 -- UTI, Alberta, Canada, and General Hospital, Boston, have been assigned a patent (8,354,110) developed by Pedro Santamaria, Calgary, Canada, and Anna Moore, Dracut, Mass., for "compositions and methods for the prevention and treatment of autoimmune conditions." The abstract of the patent published by the U.S. Patent and Trademark Office states: "The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases." The patent application was filed on March 7, 2008 (12/044,435). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,354,110&OS=8,354,110&RS=8,354,110 Written by Arpi Sharma; edited by Anand Kumar.

*** American Superconductor Assigned Patent ALEXANDRIA, Va., Jan. 18 -- American Superconductor, Devens, Mass., has been assigned a patent (8,354,136) developed by six co-inventors for a "thick superconductor films with improved performance." The co-inventors are Xiaoping Li, Westborough, Mass., Thomas Kodenkandath, N. Grafton, Mass., Edward J. Siegal, Malden, Mass., Wei Zhang, Shrewsbury, Mass., Martin W. Rupich, Framingham, Mass., and Yibing Huang, Northborough, Mass.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "A method for producing a thick film includes disposing a precursor solution onto a substrate to form a precursor film. The precursor solution contains precursor components to a rare-earth/alkaline-earth-metal/transition-metal oxide including a salt of a rare earth element, a salt of an alkaline earth metal, and a salt of a transition metal in one or more solvents, wherein at least one of the salts is a fluoride-containing salt, and wherein the ratio of the transition metal to the alkaline earth metal is greater than 1.5. The precursor solution is treated to form a rare earth-alkaline earth-metal transition metal oxide superconductor film having a thickness greater than 0.8 .mu.m. precursor solution." The patent application was filed on Nov. 24, 2009 (12/624,859). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,354,136&OS=8,354,136&RS=8,354,136 Written by Arpi Sharma; edited by Anand Kumar.

*** BioChemics Assigned Patent ALEXANDRIA, Va., Jan. 18 -- BioChemics, Danvers, Mass., has been assigned a patent (8,354,116) developed by four co-inventors for a bifunctional synthetic molecules. The co-inventors are Stephen G. Carter, Andover, Mass., Kanu Patel, Londonderry, N.H., Zhen Zhu, Tewksbury, Mass., and Lixin Qiao, Tewksbury, Mass.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "The synthesis and use of bifunctional molecules to improve the topical and transdermal delivery efficiency of various types of therapeutic agents or agents designed to promote the transdermal delivery of those therapeutic agents either into the skin tissue or into the systemic circulation. Three major classes of molecules are covalently joined as bifunctional substances; chemical vasodilators, passive dermal penetration enhancers and therapeutic or diagnostic drugs. Chemical vasodilators may be delivered into the skin to increasing the blood flow in a tissue that has compromised circulation or they may be used as part of a delivery vehicle to promote the delivery of the drug. Passive dermal penetration enhancers are those chemicals that promote the passive penetration of drugs and other chemicals through the stratum corneum and epidermis of the skin tissue. Drugs and diagnostic agents are the third group of chemicals that are candidates for the linkage of molecules." The patent application was filed on June 18, 2007 (11/820,172). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,354,116&OS=8,354,116&RS=8,354,116 Written by Arpi Sharma; edited by Anand Kumar.

*** DePuy Mitek Assigned Patent for Chondrocyte Therapeutic Delivery System ALEXANDRIA, Va., Jan. 18 -- DePuy Mitek, Raynham, Mass., has been assigned a patent (8,354,100) developed by Brooks J. Story, Franklin, Mass., Francois Binette, Weymouth, Mass., and M.E. Liesbeth Brown, West Newton, Mass., for a "chondrocyte therapeutic delivery system." The abstract of the patent published by the U.S. Patent and Trademark Office states: "Systems and methods for modifying the environment of target cell using genetically altered chondrocytes are provided. The genetically engineered chondrocytes can be used to express a therapeutic agent in a subject, including in an environment typically associated with chondrocytes and in an environment not typically associated with chondrocytes." The patent application was filed on March 23, 2011 (13/069,543). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,354,100&OS=8,354,100&RS=8,354,100 Written by Arpi Sharma; edited by Anand Kumar.

*** Siemens Medical Solutions USA Assigned Patent ALEXANDRIA, Va., Jan. 18 -- Siemens Medical Solutions USA, Malvern, Pa., has been assigned a patent (8,354,092) developed by eighteen co-inventors for a "development of molecular imaging probes for carbonic anhydrase-IX using click chemistry." The co-inventors are Hartmuth C. Kolb, Playa Del Rey, Calif., Joseph C. Walsh, Pacific Palisades, Calif., Dhanalakshmi Kasi, Los Angeles, Vani P. Mocharla, Los Angeles, Bing Wang, San Jose, Calif., Umesh B. Gangadharmath, Los Angeles, Brian A. Duclos, Kalamazoo, Mich., Kai Chen, Rockville, Md., Wei Zhang, Norwood, Mass., Gang Chen, Los Angeles, Henry Clifton Padgett, Hermosa Beach, Calif., Farhad Karimi, Mansfield, Mass., Peter J.H. Scott, Ypsilanti, Mich., Zhiyong Gao, Wynnewood, Pa., Qianwa Liang, Hacienda Heights, Calif., Thomas Lee Collier, Perkasie, Pa., Tieming Zhao, Los Angeles, and Chunfang Xia, Los Angeles.

The abstract of the patent published by the U.S. Patent and Trademark Office states: "The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents." The patent application was filed on Aug. 25, 2010 (12/862,955). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,354,092&OS=8,354,092&RS=8,354,092 Written by Arpi Sharma; edited by Anand Kumar.

For more information about Targeted News Service products and services, please contact: Myron Struck, editor, Targeted News Service LLC, Springfield, Va., 703/304-1897; editor@targetednews.com; http://targetednews.com.

-1111412 (c) 2013 Targeted News Service

[ Back To Technology News's Homepage ]